vTv Therapeutics

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HIGH POINT, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd (“G42 Investments”). Under the terms of the agreements, G42 Investments acquired 10,386,274 shares of Class A Common Stock of vTv at an issue price of $2.407 per share, with $12.5 million paid in cash at closing, and the remaining amount of $12.5 million payable on May 31, 2023. The agreements also provide for the potential issuance of $30 million in additional shares of Class A Common Stock to G42 Investments (or cash in lieu of such issuance at the option of G42 Investments) if the United States Food and Drug Administration (the “FDA”) approves the marketing and sale of a pharmaceutical product containing TTP399, a liver selective glucokinase activator, as the active ingredient for treatment of type 1 diabetes in the United States. The agreements set forth the terms under which vTv and an affiliate of G42 plan to collaborate on clinical trials for pharmaceutical products that contain TTP399, including G42's affiliate funding a portion of the Phase 3 clinical trials for TTP399, and vTv granting G42's affiliate an exclusive license to develop and commercialize pharmaceutical products containing TTP399 in certain territories outside of the United States and the European Union.

vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare

Century Casinos

Chicken Soup for the Soul Entertainment

VAALCO Energy

Harrow Health Inc

GEE Group

These seven micro-cap stocks, either due to catalysts or a low valuation, could make a move to substantially higher prices. The post 7 Mighty Micro-Cap Stocks That Could Be Future Moonshots appeared first on InvestorPlace.

7 Mighty Micro-Cap Stocks That Could Be Future Moonshots

Aileron Therapeutics

Novavax

Looking for oversold biotech stocks? These three have all seen significant drops this year despite promising catalysts for the future.

3 Oversold Biotech Stocks to Buy Now

HIGH POINT, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022, and provided an update on the progress of its clinical programs.

vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C. , March 29, 2022 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the fourth quarter and year ended December 31, 2021, and provided an update on the progress of its clinical programs.

vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update

HIGH POINT, N.C., March 3, 2022 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes, today announced that the Company has appointed Rich Nelson as Acting Chief Executive Officer.

vTv Therapeutics Announces CEO Transition

Camber Energy

Express

Here are three penny stocks to watch this week The post Best Penny Stocks to Watch This Coming Week  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Watch This Coming Week

Agriforce Growing Systems Ltd

Creative Medical Technology Holdings

Datasea Inc

Hookipa Pharma Inc

loanDepot

Maris-Tech

Revelation Biosciences

Low float penny stocks to add to your watch list right now. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 8 Low Float Stocks To Watch Right Now

The vTv Therapeutics (NASDAQ: VTVT) stock is trending today. This is why.

vTv Therapeutics (VTVT) Stock: Why Its Trending Today

HIGH POINT, N.C., Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabetes, is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral liver-selective glucokinase activator, as a transformative treatment in the reduction of hypoglycemic episodes for the global diabetes population.

vTv Therapeutics Shares Updated Corporate Presentation

Embark Technology

Schrodinger 

Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed.

3 Stocks That Can Make You Rich in Just a Few Years

vTv Therapeutics Inc (NASDAQ: VTVT) has decided to shift focus and prioritize its lead program TTP399 as it gears up for Phase 3 pivotal trials. See the pipeline here.

vTv Therapeutics Pulls The Plug On Psoriasis Candidate; Cuts Workforce By 65%

VTv Therapeutics Inc. said it reduced its workforce by about 65% as it prioritizes development of diabetes drug TTP399.

Dow Jones Newswires: VTv Therapeutics slashes 65% of workforce, focuses on its diabetes drug

vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations

vTv Therapeutics (VTVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why vTv Therapeutics (VTVT) is Poised for a Turnaround After Losing 15.2% in 4 Weeks

vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 71.43% and 130.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

VTv Therapeutics (VTVT) Reports Q3 Loss, Tops Revenue Estimates

HIGH POINT, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021, and provided an update on the progress of its clinical programs.

vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update

VTv Therapeutics (VTVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: vTv Therapeutics (VTVT) Q3 Earnings Expected to Decline

HIGH POINT, N.C., Oct. 20, 2021 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that Deepa Prasad will lead the company as President and Chief Executive Officer, effective immediately.

vTv Therapeutics Announces Deepa Prasad as New President and CEO

Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels

vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

The stock price of vTv Therapeutics Inc (NASDAQ: VTVT) increased by over 25% pre-market today. This is why it happened.

VTVT Stock: Why It Substantially Increased Today

​​​​​vTv Therapeutics Inc (NASDAQ: VTVT) announced the results of a multiple ascending dose study evaluating HPP737 in healthy adults. HPP737 is an orally administered phosphodiesterase type 4 (PDE4) inhibitor.

vTv Therapeutics Stock Gains As Psoriasis Candidate Shows Favorable Safety Profile

HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects

vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

Atossa Genetics

Clovis Oncology

Mind Medicine MindMed

PharmaCyte Biotech

Sesen Bio Inc.

VBI Vaccines

News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on InvestorPlace.

7 Penny Stocks Waiting on The FDA for Rocket Fuel

Down 16.1% in 4 Weeks, Here's Why vTv Therapeutics (VTVT) Looks Ripe for a Turnaround

News for vTv Therapeutics Stock (VTVT)